The Stock Exchange of Hong Kong Limited (the Exchange) has issued a second-stage consultation paper, in which it gives a fuller picture of the new regime aimed at attracting companies from emerging and innovative sectors to list in Hong Kong. The Exchange is aiming to implement the new rules in late April to accommodate on the Main Board the: (1) primary listing of high-growth innovative companies with weighted voting rights; (2) primary listing of pre-revenue biotech companies; and (3) secondary listing of innovative US or London-listed companies (with or without weighted voting rights) under a concessionary secondary listing route.
In this Client Briefing, we set out an overview and analysis of the new regime.
